Trastuzumab Deruxtecan Demonstrates Efficacy in HER2-positive and HER2-low Advanced Gastric Cancer
Findings from a post-hoc exploratory biomarker analysis of DESTINY-Gastric01 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable Safety in BRAF V600E–Mutated mCRC
BRAF V600E mutations are identified in 8 to 15% of patients with metastatic colorectal cancer and represent a subtype that carries a poor prognosis
Preoperative ctDNA Levels Are Detectable in the Majority of Patients with Resectable Colorectal Cancer
Findings from molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After Treatment Across a Variety of MMRd Tumour Types
Circulating tumour DNA analysis is a feasible tumour agnostic approach for evaluation of the efficacy of checkpoint blockade in patients at high risk of recurrence
Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic Colorectal Cancer
Focusing on the KRAS G12C variant
The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable Hepatocellular Carcinoma
Tislelizumab showed durable responses and was well tolerated in patients who received previous systemic treatment
EMA Recommends Extension of Therapeutic Indications for Nivolumab
New indication concerns adjuvant treatment of oesophageal or gastro-oesophageal junction cancer with residual disease following prior neoadjuvant chemoradiotherapy
Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients with Increased Nutritional Risk
Nutritional support also improved functional and QoL outcomes in a prospective, randomised, controlled EFFORT study
EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel
It is intended for the treatment of adult patiens with relapsed and refractory multiple myeloma
Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described
Genomic and histologic analyses of the KRYSTAL-1 study
ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in High-Risk Neuroblastoma
SIOPEN data contribute to the rationale for future clinical trials introducing ALK targeted treatment in the frontline setting
Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC Subtypes
The results of phase II study in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small cell lung cancers harbouring MET exon 14 skipping alterations